Qiagen and Gencurix partner on oncology diagnostic assays

VENLO, Netherlands - QIAGEN (NYSE: QGEN), a $10 billion molecular diagnostics company with excellent financial health according to InvestingPro analysis, and GENCURIX (KOSDAQ: 229000) announced a partnership to develop oncology assays for QIAGEN’s QIAcuityDx digital PCR platform, according to a press release statement.

GENCURIX becomes the inaugural partner in QIAGEN’s new QIAcuityDx Partnering Program, which aims to expand the menu of in vitro diagnostic (IVD) assays available on the QIAcuityDx Four platform. The collaboration will focus on creating multiplex oncology assays for both tissue and liquid biopsy applications.

"The first partnership in this program with GENCURIX is an exciting moment, giving our oncology testing customers access to high-quality IVD assays that complement other established methods such as qPCR and NGS," said Jonathan Arnold, Vice President and Head of Partnering for Precision Diagnostics at QIAGEN.

Under the agreement, GENCURIX will develop multiple oncology assays and pursue IVD regulatory approvals as the legal manufacturer. Once approved, the assays will be marketed through QIAGEN’s global commercial infrastructure.

The partnership leverages QIAGEN’s QIAcuityDx platform, which is part of the QIAcuity family of digital PCR systems that reached more than 2,700 cumulative placements by the end of 2024. With a robust gross profit margin of 67% and strong liquidity position, QIAGEN is well-positioned to support this expansion. The collaboration aims to address growing demand for broader access to high-precision diagnostic assays in clinical laboratories. InvestingPro data reveals 10 additional growth and financial strength indicators for QIAGEN, available in the comprehensive Pro Research Report.

Digital PCR technology is increasingly recognized as complementary to existing methods like qPCR and NGS, particularly in oncology, infectious diseases, and rare genetic disorders. Based on InvestingPro’s Fair Value analysis, QIAGEN’s stock is currently trading near its fair value, reflecting market confidence in its technological leadership and growth prospects.

In other recent news, QIAGEN has announced an increase in its full-year 2025 adjusted diluted earnings per share (EPS) outlook, now expecting approximately $2.35, up from a previous projection of $2.28. Preliminary first-quarter results also show adjusted EPS estimated at least 55 cents, surpassing the Bloomberg Consensus estimate of 49 cents, with net sales at constant exchange rates reaching $483 million. Additionally, QIAGEN has completed the acquisition of Genoox for $70 million, with potential additional milestone payments, to enhance its genetic data analysis capabilities. This acquisition introduces Genoox’s Franklin platform into QIAGEN’s Digital Insights suite, aiming to improve clinical decision support in genetic diseases. In a strategic move, QIAGEN plans to propose an annual cash dividend of $0.25 per share, pending shareholder approval, reflecting a balance between shareholder returns and growth investment. Furthermore, QIAGEN has entered a strategic partnership with Foresight Diagnostics to develop a kit-based version of the CLARITY™ assay for cancer diagnostics. Meanwhile, Redburn-Atlantic has downgraded QIAGEN’s stock rating from Buy to Neutral, adjusting the price target to EUR41, citing a more mature growth trajectory in certain business segments. These developments highlight QIAGEN’s ongoing efforts to enhance its market position and financial performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.